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The interaction between CMV and its human host is complex and constitutes 
many levels. Millions of years of co-evolution have enabled CMV to manipulate the 
extent and quality of the host immune system, which allows it to establish latency and 
cycles of lytic infection [1]. CMV does not completely eliminate host immunity, but 
modulates it to overcome one of the broadest and strongest T cell responses analyzed 
to date [2]. This is essential in the life cycle of the virus, and ensures survival of both 
virus and host [1]. However, the success of this intricate and delicate balance between 
CMV and host is dependent on immunocompetence of the host. This prerequisite is 
clearly unfulfilled under immunosuppression, and results in significant morbidity 
and even mortality in recipients after renal transplantation [3]. 
Here we performed clinical and experimental studies to better understand the 
impact and mechanisms underlying human cytomegalovirus (CMV) infection, the 
most important infection in renal transplant recipients. These studies entail the level 
of the patient, tissue and cells, so to be able to explore both the functional outcome 
and the potential mechanisms. This provides additional insights into the effects of 
CMV that can ultimately contribute to maintain kidney function and improve the 
outcome of renal transplantation. 
In chapter 2 we have demonstrated the intermediate and long-term irreversible 
and sustained loss of renal function after pronounced CMV DNAemia, the most 
generally applied method for detection and diagnosis of CMV in the clinic. A CMV 
peak viral load (PVL) exceeding 6310 international units/ml was associated with a 
lower eGFR (estimated glomerular filtration rate) independently of recipient, donor 
and transplantation characteristics. This indicated that recipients have long-term 
sequelae up to three years post-transplantation and that CMV-induced renal damage 
does not recover. It is important to consider that most likely not the infection in itself, 
but the extent of CMV DNAemia and its indirect effects affect renal function. Ideally, 
regular and intensive monitoring would allow physicians to contain CMV infection 
before it exceeds the critical threshold, which was defined by us as a PVL of 6310 
IU/ml. The importance of containing CMV infection is also reflected in chapter 3, 
where we studied virus burden by quantifying CMV using the duration of infection. 
We found that prolonged CMV DNAemia was associated with increased risk for graft 
failure, both overall and death-censored, as well as with decreased eGFR at 12 months 
post-transplantation. This indicates that CMV-induced renal function decline can 
result from a higher extent of DNAemia, but alternatively from its extended duration.
This threshold of 6310 IU/ml (chapter 2) might be applied in the clinical setting, 
but commutability of CMV assays between institutes remains a challenge. This is due 
to the variability in for example specimens, amplification targets and instrumentation 
used amongst others [4, 5], and the collective of methods that are applied [6]. For 
example, the type of infection could affect in which blood compartment CMV is most 
productively detected, making it essential to monitor subjects using only a single 
type of specimen [7, 8]. Quantitative differences in limits of detection and reported 
results [5] lead to difficulties comparing findings between institutes and establishing 




























universal guidelines for intervention [6, 9]. This substantiates the necessity for 
comparable benchmark thresholds for CMV detection and intervention, so to ensure 
quality of patient care. Despite an international reference standard [6, 10] and FDA 
approval for a universal assay of CMV quantification in plasma [11], the challenges 
of harmonization remain. Focus on characterizing and improving commutability 
of CMV detection are thus essential to enable portability of results, standardized 
therapeutic thresholds and uniform interpretation [6].
Additionally, the lack of straightforward interpretation of detected viral loads 
for CMV disease and the absence of established consensus on the exact threshold 
for initiation of antiviral therapy, complicate interpretation of CMV infection [12]. 
This can result in overtreatment with accompanying unnecessary side-effects and 
high therapeutic costs on the one hand, while on the other hand it may cause under-
treatment and progression towards symptomatic disease [13]. With that, the precise 
immunosuppressive regimen varies substantially between transplant institutions 
and consensus on the optimal immunosuppressive regimen is lacking [14]. It is 
therefore important to take the background of the recipient, immunological risk and 
drug characteristics into account when determining the specific threshold for every 
individual recipient. 
Serological diagnosis of CMV infection after renal transplantation is complex 
since immunosuppression inhibits the immune response from developing according 
to its natural course. This contributes to preventing rejection of the transplanted 
organ, but additionally complicates interpretation of immunological parameters. The 
humoral and cellular arm of the immune system are in constant interplay, providing 
an important role for anti-CMV antibodies indirectly. Preformed CMV antibodies 
may aid immunosuppressed patients to prevent or limit dissemination during 
reactivation, but their exogenous administration showed only limited benefit [15]. It 
is important to realize that viral replication occurs intracellularly and therefore NK 
cells and the cellular immune response are pivotal to restrain infection, which cannot 
be directly attenuated by antibodies alone [16]. Nevertheless, antibody production is 
essential for the fetus in preventing congenital infection and for premature infants 
to impede transfusion-associated infection [15]. Also, positive results have been 
achieved with vaccines that stimulate neutralizing antibodies, for instance against 
the glycoprotein H complex [17].
Interestingly, our studies indicate that longer time-to-CMV IgM seroconversion, 
so a delayed CMV IgM seroresponse, was related to decreased eGFR and more 
pronounced graft failure (chapter 3). It suggests that the initiation of the CMV IgM 
response after infection provides information about the extent of renal damage, 
supposedly caused by CMV. Clinically, primarily CMV IgG antibodies are used, to 
determine previous history of CMV infection before transplantation. Now, measuring 
CMV IgM at 25 days post-infection (the median anti-CMV IgM seroconversion 
time) could provide an intermediate indication on the initiation and maturation of 
the adaptive immune response, and whether intervention is necessary. Although a 
direct role for CMV IgM in diagnoses is not likely, it could follow the CMV PCR 
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used to determine the recipient’s CMV infection, and supplement it regarding 
development of the immune response. It could indicate the necessity for adapting 
therapeutic intervention, for instance the anti-CMV medication and tapering of 
immunosuppression. 
Reduction of immunosuppression, particularly MMF, is a strategy to potentiate 
and reinstate antiviral immunity of the host. This study demonstrated that prolonged 
duration of MMF treatment associated to extended CMV DNAemia, a delayed 
CMV IgM and CMV IgG seroresponse and decreased eGFR at 12 months post-
transplantation (chapter 3). In this subpopulation of recipients, withdrawal of MMF 
is potentially beneficial for shortening CMV DNAemia and development of a CMV 
immune response without additional risk for cellular rejection. It could point towards 
an adapted strategy regarding MMF treatment to allow the recipient’s immune system 
to thrive against the viral infection. Regular measurements of CMV DNAemia and 
anti-CMV IgM could distinguish those subjects displaying a slow immune response 
who are more prone to infectious complications, and identify subjects eligible for 
withdrawal of MMF early. 
Next to studying the effect of withdrawing immunosuppressive medicine, we were 
interested to explore the immunoregulatory potential of the body itself, specifically 
by regulatory B cells. Down-regulation of these cells could provide an alternative 
approach to withdrawal of immunosuppressive therapy, which we studied for MMF 
in chapter 3. In chapter 4 we evaluated B cell phenotyping as a measure of predicting 
transplant rejection in renal transplant recipients. Pre-transplant transitional 
CD24hiCD38hi or memory CD24hiCD27+ B cell subsets, presumably containing a 
regulatory B cell population, did not differ between subjects with biopsy-proven 
acute rejection (BPAR) and those without, neither by percentages, absolute numbers 
or survival free from BPAR. A potential reason is that it is still undetermined whether 
Bregs actually represent a dedicated lineage within the B cell population, or gain 
regulatory capacity in response to their distinct microenvironment or particular B 
cell receptor [18]. Alternatively they could result from the expansion of short-lived 
effector cells in response to inflammation, or differentiation secondary to resolution 
of the inflammatory response. Although cytokines and cell surface markers for Bregs 
have been identified, no lineage–specific molecular marker can uniquely identify 
regulatory B cell subsets [19]. This may result in biased model systems investigating 
heterogeneous populations of suboptimally defined regulatory cells, that are mixed 
with other B cell sub–populations from various developmental states, anatomic 
locations and functional capacity [18].
Although B cell subsets did not vary for CMV seropositive or seronegative 
recipients before transplantation, post-transplantation CMV infection was more 
prominent for patients with the highest percentage of transitional CD24hiCD38hi B 
cells (chapter 4). CMV peak viral load as measure for infection did not correlate 
to percentage of transitional CD24hiCD38hi or memory CD24hiCD27+ B cells. From 




























these association studies it is difficult to comment on the mechanism underlying 
the role of transitional CD24hiCD38hi and memory CD24hiCD27+ B cells on CMV 
infection post-transplantation. Nevertheless, we could speculate that negative 
regulation of the innate and adaptive immune responses by Bregs may indirectly also 
suppress protective host responses against pathogens and increase susceptibility to 
infections. For instance, the frequency of Bregs positively correlated with enhanced 
viral replication of chronic hepatitis B virus [20] and IL-10 levels were temporally 
closely associated with viral load [21]. 
Further studies exploring the relationship and mechanism between Breg 
homeostasis and CMV infection should be conducted to provide further insight. 
These could include studying Bregs in co-culture with CMV antibody-producing 
B-cells in vitro, the temporal IL-10 (and potentially cmvIL-10) production after 
transplantation and its correlation with peak viral loads. Adopting the theory that 
Bregs gain regulatory capacity in response to their distinct microenvironment, 
it would be very insightful to determine whether inhibition of this maturation 
is favorable for preventing CMV infection. The frequency or composition of the 
regulatory B cell compartment may serve as a minimally invasive monitoring tool 
to guide immunosuppressive strategy and identify recipients eligible for tapering 
of immunosuppression (for instance MMF in chapter 3) [22]. Personalization 
may prevent over-immunosuppression accompanied by malignancies, infections 
and cardiovascular events on the one hand, and under-immunosuppression with 
consequent acute and chronic rejection on the other [21]. 
Although it is unlikely to find large-scale practical application on the short term, 
immune regulation and principles learned from clinical tolerance are expected to 
provide important tools for transplantation in the future. Nevertheless, the effect of 
immunosuppression and the validity of tolerance biomarker signatures should be 
further characterized before introduction into clinical practice [22, 21]. This should 
be constrained by stringent quality restrictions considering the risk for acute rejection 
or graft damage [23]. While awaiting such comprehensive tolerance signatures, Breg 
characterization and cytokine profiling may provide surrogate markers to gauge 
immune regulation. 
One of the characteristic properties of CMV is its immunomodulatory capacity, 
which allows it to modulate the host immune response. An alternative strategy to 
limit the detrimental effects of CMV infection would thus interfere with this capacity, 
to make it more vulnerable to clearance by the immune system. We decided to 
focus on CMV-encoded G protein-coupled receptor US28, given its most extensive 
characterization and potential as accessible target for intervention. 
In chapter 5 we have demonstrated CMV-encoded viral G protein-coupled 
receptor US28 in vessels during productive and latent infection. Its expression was 
restricted to vascular smooth muscle cells and tubular epithelial cells after renal 
transplantation, while permissive infection was not restricted to a particular renal 
cell type. The segmental localization of US28 suggested that CMV regulates antigen 
Chapter 7
116
expression in response to, or interaction with, the specific microenvironment that 
the infected cell resides in. Against our expectations, US28 and immediate early 
antigen expression regularly did not overlap. This is an intriguing finding, for which 
conclusive insight into the underlying mechanism is currently lacking. However, 
immediate early antigen may be favored during the initial infection when the virus 
focuses on host cell control and immune evasion, while US28 expression in vascular 
smooth muscle cells might enable further infiltration of the underlying tissue or 
neointima. 
By committing a substantial portion of its genome to immune modulation and 
evasion, CMV gains a temporary advantage that protects it from the antigen-specific 
host immune response and allows release of viral progeny, infection of neighboring 
cells and dissemination to more distant sites [15]. Recently, it was demonstrated that 
next to its multifunctional role during productive infection, US28 is also important 
during latency [24]. Despite vast limits to the viral transcription machinery during 
latency, a selection of proteins is expressed and profoundly affects the infected cells 
and cellular microenvironment. Intriguingly, expression partly overlaps with that 
during productive infection, which makes one wonder about why latently infected 
cells are immunoprivileged and not effectively targeted [25]. A mutant CMV solely 
expressing US28 (without the other three CMV-encoded GPCRs) could maintain 
latent infection, while a US28-deficient CMV induced the major immediate early 
promoter and production of infectious virus [24]. 
Development of suitable in vitro approaches for latency would yield great benefit 
for translating in vitro findings on CMV into clinical practice. It remains essential 
to determine whether CMV latency serves ‘just’ as shutdown of normal replication 
or as a process which is latency-specific. Is it interrupted active infection induced 
deliberately by the virus or is it forced upon the virus by the immune system? If the 
former is the case, does US28 play a role in this? What is the potential for therapeutic 
intervention? These considerations are expected to further expand our understanding 
of CMV latent infection and reactivation and explore it as important targets for future 
therapy, especially since latency often precedes clinical manifestation of disease [24]. 
We also showed that US28-deficiency significantly impeded viral spreading 
in vascular smooth muscle cells, particularly through cell-to-cell contact (chapter 
5). US28 expression in VSMCs might enable spreading of CMV by binding to 
chemokines immobilized on neighboring cells, such as CX3CL1 (fractalkine) [26]. 
Since VSMCs in atherosclerotic lesions express membrane-bound CX3CL1 to a high 
extent, US28 could promote cell-to-cell interactions and promote viral spreading 
[27]. This would be a suitable focus for intervention, targeting the binding location 
for CX3CL1 and preventing US28 activation. Even though 26% of all registered drugs 
are directed against G protein-coupled receptors, these drugs modulate only 7% of 
all underlying targets and leave the large majority of targets unaffected [28]. Several 
non-peptide compounds can inhibit ligand binding to US28 directly or as allosteric 
modulators, or reduce the constitutive activity of US28 [29]. Although promising 




























as therapeutics for anti-viral intervention, their micromolar potency limits in vivo 
applicability [30]. The increased interest in llama-derived antibodies targeting 
GPCRs and more particularly chemokine receptors, so called nanobodies [31, 32] 
[33], provides opportunities to modulate (viral) chemokine receptor function. 
From our findings on the localization of US28 in transplant biopsies and in vitro 
viral spreading experiments, we were interested to further characterize the functional 
effects of US28 on vascular smooth muscle cells (chapter 6). To study US28 in detail, 
an in vitro inducible US28 model system of vascular smooth muscle cells (VSMC-
iUS28) was developed. The US28 expression levels in iUS28-VSMCs resembled 
those of WT CMV-infected VSMCs, suggesting it provides a suitable model system 
for US28 after CMV infection. Expression of US28 resulted in elevated secretion of 
VEGF and L-lactate, which suggests transition to a more dedifferentiated phenotype. 
Since upregulation of VEGF stimulates angiogenesis and the VEGF receptor, and 
angiogenesis in the intima could contribute to coronary artery vasculopathy, this 
supports a role for US28 in transplant vasculopathy [34, 35]. The suspected lower 
expression of α-SMA in CMV-infected compared to non-infected VSMC points 
towards dedifferentiation away from its contractile phenotype. Hence, these findings 
support a potential US28-dependent phenotypic switch of VSMCs to a more 
proliferative and synthetic phenotype. 
US28 expression on the virion, cell surface and during latency make it an attractive 
and suitable target for intervention. High affinity (nM) US28-specific nanobodies 
could supersede the antigen-specificity of current compounds used to inhibit US28. 
An interesting recent technology utilizing the rapid and ligand-independent receptor 
internalization for US28 is that of fusion toxin protein [36]. Fusion toxin proteins 
utilize high-affinity receptor–ligand interactions to direct toxins towards their target. 
Nanobodies fused to toxins may access epitopes impenetrable to conventional 
antibodies and further strengthen the potency and efficacy of this antiviral strategy 
[36].
One concern for targeting viral GPCRs is selectivity and risk for aspecificity 
because of their homology to human cellular receptors. Obviously, preventing 
unintended modulation of cellular chemokine receptors is of the utmost importance. 
Biased signaling, or functional selectivity, occurs widely in the chemokine system 
and may contribute to specifically modulating viral GPCRs. This process describes 
preferential activation (bias) of a particular cellular signaling pathway and functional 
outcome depending on the specific ligand, receptor and cell combination. Functional 
selectivity allows a more focused approach to specifically target a particular receptor 
conformation, potentiate drug efficiency and limit side–effects [37]. The high 
selectivity of nanobodies may be beneficial in targeting viral GPCRs.
Interestingly, US28 expression in US28-deficient CMV-infected cells suggested 
increased lytic cell death. This could be due to US28 accelerating lytic replication of the 
virus, through which intervention could inhibit viral spreading and resulting CMV-
induced effects. Although unlikely to completely prevent the viral spreading of CMV 
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over the monolayer, interfering with US28 could slow down infection of the cells. 
This allows for an interesting method for intervention, but additional experiments 
are required to further characterize its potential. For instance clarification of the 
affected intracellular signaling pathways can shed additional light on its role.
Interaction between CMV and the host
It is important to further elucidate the exact interaction between CMV and the 
host immune system that allows for cycles of latency and lytic infection [1]. On the 
one hand, the pro-inflammatory environment surrounding infected cells provides 
a benefit for viral replication or dissemination within the host [1, 38]. On the 
other hand, CMV employs multiple strategies to avoid efficient recognition by and 
activation of the immune system and thereby evade elimination [1]. One strategy of 
particular interest is cmvIL-10, the viral homologue of human anti-inflammatory 
cytokine IL-10 [25]. IL-10 is important during immune regulation by regulatory B 
cells, which points towards attempts of CMV to modulate the host immune response 
using similar mechanisms. It would be insightful to study the effects of cmvIL-10 
on immune modulation, inflammation and infection and determine whether its 
mechanisms overlap with those induced by regulatory B cells. 
We have found that both the extent of CMV DNAemia early after transplantation, 
as well as the duration of CMV DNAemia were associated with worse renal outcome 
after transplantation. This emphasizes the importance of restraining CMV in renal 
transplant recipients. Our findings may not only provide insight into CMV in the 
context of renal transplantation, but also indications for transplantation of the liver, 
heart, lung and pancreas that likewise necessitate immunosuppression [39]. CMV 
disease is a widespread complication after transplantation, with an incidence that 
varies extensively based on factors including donor–recipient serological matching, 
immunosuppressive regimen and type of organ [40]. For instance, the incidence is 
50 – 75% for lung or heart–lung, 9 – 23% for heart and 22 – 29% for liver in absence 
of prophylaxis [40]. It remains to be determined whether findings in solid-organ 
transplant recipients can be extended to other groups of immunocompromised 
subjects, such as HIV-infected subjects and allogeneic hematopoietic stem cell 
recipients. The extensive group of potential beneficiaries further strengthens the 
imperative for improving prevention and treatment of cytomegalovirus inside and 
outside of the clinic.
On the cellular level it is important to untangle the potential different functions 
that US28 may perform depending on viral stage, environment of the infected 
cell or during in vitro and in vivo infection. Development of a suitable in vitro 
approach for latency would greatly benefit aligning experimental findings to the 
clinic. Furthermore, an essential future step involves the generation of a suitable in 
vivo model undergoing infection, which would allow characterization of US28 in 
interaction with the host immune system. 




























Unfortunately an ongoing challenge for research on CMV pathogenesis is 
the current lack of a suitable animal model. The extensive co-evolution between 
CMV and its host has allowed CMV to efficiently replicate and disseminate in 
its own (or closely related) host species, but also resulted in a limited host range. 
This substantially complicates the applicability of animal models for studying host 
receptors, viral entry, intracellular host defenses and specific cytokine responses [41]. 
Great progress may be achieved using human immune system mouse technology, 
which allows the study of human-restricted viruses directly in vivo. This approach 
enables engraftment of human cells into mice whose immune system was replaced by 
human hematopoietic progenitor cells. These models are increasingly implemented 
in studies of CMV latency and reactivation, its establishment and maintenance, viral 
genetics and antiviral drugs. However, only a small selection of the large variety 
of CMV infection-associated diseases has been recapitulated in humanized mice. 
Obviously it is challenging to reliably and reproducibly mimic human CMV infection 
in in vivo models, but further exploration holds attractive promise for the future [42]. 
Humanized mouse models could represent a valuable tool in the ongoing effort to 
characterize and modulate CMV infection and pathogenesis, for instance regarding 
the role of regulatory B cells in transplantation, but also to test efficacy of anti-US28 
therapies in vivo. 
 
Treatment of CMV infection
The preemptive therapy in the cohort of chapter 2 enabled CMV peak viral loads 
to be studied without anti-CMV treatment right after transplantation. Obviously, 
the very act of treating subjects is interfering with the potential rise in viral load, 
but this is intrinsic to the purpose of treatment, i.e. limiting productive CMV 
infection. Intrinsic difficulties with current anti-CMV treatment include toxicity 
of available drugs, as well as the necessity for intensive laboratory surveillance, 
CMV immunomodulatory effects and late-onset CMV disease [43]. On top of that, 
recipients with intensive immunosuppression and sustained ganciclovir treatment 
are especially vulnerable for resistance [44], and display more tissue-invasive disease 
and worse clinical outcome [45]. Development of new drugs with reduced adverse 
profiles and new targets are therefore of significant importance.
We have found that high peak viral load is associated with decreased eGFR 
(chapter 2), but have not studied the factors determining the height of PVL. Next to 
high PVL as a cause of decreased renal function, it additionally may be a consequence 
of it. Pre-existing donor and / or recipient characteristics could make renal cells 
increasingly susceptible to CMV infection. Factors such as longer ischemia times, 
more HLA mismatches or older age could predispose recipients to a quicker or more 
severe incline in viral load. Future studies should shed additional light on the factors 
responsible for the rise in peak viral load, and provide targets for intervention.
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Although we cannot directly assess the effect of an immunosuppressive regimen 
without MMF, these findings suggest that MMF may be safely withdrawn in this 
population of primary infected renal transplant recipients. Nevertheless, it has 
been previously demonstrated that renal function, allograft survival and acute 
rejection rates benefit from treatment with daclizumab, corticosteroids and low-dose 
tacrolimus in combination with MMF [46]. Further research should thus indicate 
whether our findings can be safely translated to a broader population of patients, 
since rejection could still pose a risk. 
Well-timed interference is of particular importance to restrain CMV and its 
detrimental effects after renal transplantation. Regular and extensive monitoring 
of the evolving CMV infection is necessary as well as compliance to antiviral 
medication. The occurrence of late-onset CMV disease and drug toxicity indicate 
that prophylactic CMV therapy may not be an optimal final solution, and warrants 
additional alternative strategies. One obvious strategy is that of “CMV matching”; 
exclusively selecting CMV-negative donors for donating to CMV-negative recipients 
to decrease the risk for CMV infection. Ideally, donor and recipient matching will 
contribute to graft survival, but the seroprevalence of CMV will inevitably extend 
the time on the waiting list, which is deemed unacceptable. At most, donor CMV-
seronegativity could be included as preference criterion for living donation into 
CMV-seronegative recipients, when multiple suitable donor candidates are available. 
An ultimate solution to prevent CMV infection altogether is still far from practical 
reality [47]. Immunotherapy with CMV vaccines provides an attractive option 
because of its effectivity and ease of administration [43]. Its high-priority status has 
supported cooperation within the fields of virology, immunology, epidemiology and 
clinical trials in an effort to decrease the disease burden, cost and human suffering 
associated with CMV [48]. These efforts contribute to alleviate CMV not only in post-
transplant disease, but also other medical conditions including congenital infection, 
atherosclerosis, glioblastoma and immunosenescence [49]. Several candidate 
vaccines (e.g. against glycoprotein B) have reached preclinical and clinical testing 
[50], but none have been licensed so far [51]. Important questions that remain include 
to what extent suppression in viral load can be expected after vaccination, and what 
extent is necessary to prevent clinical manifestations of CMV [43]. With that, severe 
immunosuppression in the recipient may hamper effective immunization, which 
suggests that immunization before transplantation may be a more effective strategy 
[52]. An analysis in adolescent females prior to their first pregnancy indicated that 
CMV vaccination would be less costly and result in greater clinical benefits [53], 
suggesting it may be a viable approach to contain CMV infection. 
Although among many immune modulatory strategies employed by CMV, US28 
is one of the most widely characterized. Nevertheless, little is known about its role 
in (renal) transplantation. Since the vasculature is one of the components affected 
during chronic renal transplant dysfunction, US28 constitutes a potential target for 
therapeutic intervention. Targeting US28 could enable a larger therapeutic window by 
slowing down the initial viral dissemination, and containing CMV-induced damage.




























A recent and promising strategy to overcome problems associated with CMV 
is the application of camelid-derived antibodies, so called nanobodies (Nbs). 
These have gained interest in the last decade for their suitable characteristics and 
therapeutic potential, providing a promising strategy in targeting human and viral 
proteins [54]. Nanobodies are recombinant antigen-specific variable domains that 
represent suitable candidates for modulating immune functions and targeting toxins 
and pathogens, both in research as well as clinical application [54, 55]. 
The therapeutic applications for nanobodies that are currently explored and 
developed range from diagnostic imaging, brain drug delivery, and targeting of 
receptors (CXCR4, CXCR7) and chemokines (CCL2, CCL5, CXCL11, CXCL12) 
[31 - 33, 56]. Although no nanobodies have actually been approved for therapeutic 
applications, research is rapidly developing into areas such as increasing stability of 
GPCR targets, tracking of proteins in live cells, and selective manipulation of specific 
signaling pathways 31]. Nanobodies could provide an interesting replacement, 
or complementation, for conventional antibodies in targeting G protein-coupled 
receptors in a variety of diseases (e.g. inflammatory diseases, metabolic disease 
and malignancies). US28 provides a suitable target for intervention, and may be 
complemented by other CMV antigens, including the other viral GPCRs and 
important structural proteins such as pp65, pp50, gB, and IE-1 [57]. Nanobody-based 
therapies could be used to complement and reinforce current antiviral strategies, 
before possibly replacing them altogether someday. It could be particularly suitable 
for those recipients experiencing resistant CMV, allowing for an additional angle to 
target the CMV infection. 
First and foremost, despite the challenges to maintain renal graft function, 
renal transplantation remains the preferred choice of treatment for (pre)terminal 
renal failure due to substantial medical and economic benefits. Medically, kidney 
transplantation is associated with significantly lower mortality, lower risk for 
cardiovascular events and improved quality of life compared to chronic dialysis, and 
these factors relatively increase over time [58]. For instance, transplant recipients had 
a 48 - 82% lower long-term mortality rate compared to patients on the waiting list 
[59]. A rough estimation indicated almost €15.000 of savings per year for a patient 
after transplantation compared to dialysis [60] and lower costs per quality-adjusted 
life year [61]. 
One factor that nourishes optimism for the future of transplantation is the 
decreasing waiting list, increased total number of effectuated organ donors and 
increased number of transplantations from living donors between 2011 and 2015 [62]. 
These positive developments could be further reinforced by raising and stimulating 
societal awareness about transplantation. It remains of vital importance to involve 
and educate the public about the importance of transplantation and find new ways to 
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